RANKL plays an important part in mediating bone resorption by accelerating the formation and function of osteoclasts.[8] The efficacy of denosumab against osteoporosis was revealed by a large randomized clinical trial of long duration: Fracture Reduction Evaluation of Denosumab in Osteoporosis every 6 Months (FREEDOM).[9]. Here, TNFSF11 is linked to osteoporosis.